| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
PPARα
PPARgamma (Peroxisome Proliferator-Activated Receptor gamma); and potentially other nuclear receptors involved in lipid metabolism and inflammation. (10E,12Z)-Octadeca-10,12-dienoic acid is a ligand for PPARgamma. |
|---|---|
| ln Vitro |
(10E,12Z)-Octadeca-10,12-dienoic acid inhibits the proliferation of human gastric adenocarcinoma SGC-7901 cells, cell nuclear division, colony formation, and DNA synthesis, while inducing cell differentiation. It modulates the expression of genes involved in lipid metabolism and inflammation. The specific IC₅0 for cell growth inhibition varies by cell line.
|
| ln Vivo |
This entry is not available. As an isomer of conjugated linoleic acid, (10E,12Z)-octadeca-10,12-dienoic acid is expected to have in vivo effects on body composition, insulin sensitivity, and inflammation. In animal models, t10,c12-CLA reduces body fat mass and can induce lipoatrophy at high doses.
|
| Enzyme Assay |
A general cell-free protocol for PPARgamma binding: A fluorescence polarization (FP) competitive binding assay is used. Recombinant human PPARgamma ligand-binding domain (LBD) protein (GST-tagged, 5 nM) is incubated with a fluorescently labeled PPARgamma ligand (Fluormone PLM Red, 1 nM) in a buffer (100 mM potassium phosphate, pH 7.4, 100 ug/mL BSA, 0.01% NaN3) at room temperature for 2 hours. Varying concentrations of (10E,12Z)-Octadeca-10,12-dienoic acid (0.01 nM to 100 uM) are added to the mixture. The fluorescence polarization (FP) signal is measured using a microplate reader with polarization filters. The IC₅0 is calculated, and the Kᵢ is derived using the Cheng-Prusoff equation. The assay is performed in 384-well black plates with a total volume of 25 uL per well.
|
| Cell Assay |
A general cellular protocol for assessing PPARgamma activation: 3T3-L1 preadipocytes are seeded in 12-well plates and maintained until confluence. Two days post-confluence, the cells are treated with differentiation medium (DMEM containing 10% fetal bovine serum, 1 uM dexamethasone, 0.5 mM IBMX, and 1 ug/mL insulin) in the presence or absence of various concentrations of (10E,12Z)-Octadeca-10,12-dienoic acid (1, 10, 50, 100 uM) for 48 hours. The medium is then replaced with maintenance medium (DMEM + 10% FBS + 1 ug/mL insulin) containing the same concentrations of the test compound. Oil Red O staining is performed on day 8 to quantify lipid accumulation. Triglyceride content is measured using a commercial kit. Alternatively, the expression of PPARgamma target genes (e.g., aP2, LPL) is measured by qRT-PCR after 6-12 hours of treatment.
|
| Animal Protocol |
General animal protocol for evaluating the anti-obesity effects of fatty acids: Male C57BL/6J mice are fed a high-fat diet (HFD, 60% kcal from fat) for 8 weeks to induce obesity. The mice are then randomized into treatment groups (n=10/group). (10E,12Z)-Octadeca-10,12-dienoic acid is administered via oral gavage at doses of 50, 100, and 200 mg/kg/day for 6 weeks. The vehicle control group receives an equal volume of corn oil. Body weight and food intake are measured weekly. At the end of the study, blood is collected for serum lipid analysis (triglycerides, total cholesterol, HDL, LDL) and insulin levels. Epididymal and subcutaneous white adipose tissues are dissected and weighed. Liver and adipose tissues are processed for histopathological examination. Body composition is analyzed by EchoMRI.
|
| ADME/Pharmacokinetics |
General pharmacokinetic protocol for fatty acids: Male Sprague-Dawley rats are administered (10E,12Z)-Octadeca-10,12-dienoic acid via oral gavage (PO, 100 mg/kg) and intravenous (IV, 10 mg/kg) injection. Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose. Plasma concentrations of the compound are quantified by LC-MS/MS. PK parameters (Cmax, Tmax, AUC, t½, clearance, Vd, and oral bioavailability F%) are calculated using non-compartmental analysis. As a fatty acid, the compound is expected to be highly protein-bound and to have a short half-life due to rapid metabolism via beta-oxidation.
|
| Toxicity/Toxicokinetics |
General toxicity protocol for fatty acids: A 90-day repeated-dose oral toxicity study is performed in Sprague-Dawley rats. (10E,12Z)-Octadeca-10,12-dienoic acid is administered via oral gavage at doses of 250, 500, and 1000 mg/kg/day. A control group receives corn oil. Clinical signs, body weight, and food consumption are recorded daily. Hematological parameters (complete blood count) and serum chemistry (ALT, AST, BUN, creatinine, total protein, albumin, glucose, triglycerides, cholesterol) are measured at the end of the study. Gross necropsy is performed, and the weights of major organs (liver, kidney, heart, spleen, lung, brain, testes) are recorded. Histopathological examination is conducted on these organs. High doses of t10,c12-CLA are known to induce hepatic steatosis and insulin resistance in some animal models.
|
| References |
|
| Additional Infomation |
(10E,12Z)-octadecadienoic acid is an octadecyl-10,12-dienoic acid with a (10E,12Z) configuration. It is the conjugate acid of (10E,12Z)-octadecadienoic acid ester. (10E,12Z)-octadecyl-10,12-dienoic acid has been reported in taro (Colocasia antiquorum) and edible taro (Colocasia esculenta), and relevant data are available.
(10E,12Z)-Octadeca-10,12-dienoic acid is an isomer of conjugated linoleic acid (CLA). The molecular formula is C1₈H32O2, and the molecular weight is 280.45 g/mol. The compound is a liquid at room temperature, with a density of 0.9+/-0.1 g/cm3 and a boiling point of 381.6+/-11.0degC. The logP value is 7.18, indicating high lipophilicity. For storage, the powder is stable at -20degC for 3 years and at 4degC for 2 years. The compound is soluble in DMSO and ethanol. |
| Molecular Formula |
C18H32O2
|
|---|---|
| Molecular Weight |
280.45
|
| Exact Mass |
280.24
|
| CAS # |
2420-56-6
|
| PubChem CID |
5282800
|
| Appearance |
Liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
381.6±11.0 °C at 760 mmHg
|
| Flash Point |
278.5±14.4 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.478
|
| LogP |
7.18
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
20
|
| Complexity |
267
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C=C\CCCCCCCCC(=O)O
|
| InChi Key |
GKJZMAHZJGSBKD-NMMTYZSQSA-N
|
| InChi Code |
InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-9H,2-5,10-17H2,1H3,(H,19,20)/b7-6-,9-8+
|
| Chemical Name |
(10E,12Z)-octadeca-10,12-dienoic acid
|
| Synonyms |
trans-10,cis-12 CLA2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5657 mL | 17.8285 mL | 35.6570 mL | |
| 5 mM | 0.7131 mL | 3.5657 mL | 7.1314 mL | |
| 10 mM | 0.3566 mL | 1.7828 mL | 3.5657 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
